Ziftomenib Approved for Certain Acute Myeloid Leukemias
The FDA has approved the menin inhibitor ziftomenib for adults with relapsed or refractory acute myeloid leukemias harboring susceptible...
Progress Against Cancer
The FDA has approved the menin inhibitor ziftomenib for adults with relapsed or refractory acute myeloid leukemias harboring susceptible...
The FDA approved daratumumab and hyaluronidase-fihj for adults with smoldering multiple myeloma that has a high risk of progression. ...
The FDA has approved the menin inhibitor revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1...
The FDA approved the BCMA-targeted antibody-drug conjugate belantamab mafodotin-blmf as part of a combination therapy for adults with refractory...
The FDA approved cemiplimab-rwlc as an adjuvant therapy for patients with cutaneous squamous cell carcinoma at high risk of...
The FDA has approved the DNA-damaging agent in combination with immunotherapy for patients whose cancers have not progressed after...
The FDA has approved imlunestrant for certain patients with advanced ESR1-mutated breast cancer that has progressed following previous endocrine...
The FDA approved pembrolizumab and berahyaluronidase alfa-pmph as an injectable therapy for multiple tumor types. The U.S. Food and...
FDA expands selumetinib approval to include pediatric patients as young as 1 year with inoperable plexiform neurofibromas. The U.S....
The FDA has approved a delivery system that, once inserted into the bladder, delivers a local dose of the...